140 related articles for article (PubMed ID: 2868560)
1. Effect of perfluorochemical (Fluosol-DA) on infarct morphology in dogs.
Kolodgie FD; Dawson AK; Forman MB; Virmani R
Virchows Arch B Cell Pathol Incl Mol Pathol; 1985; 50(2):119-34. PubMed ID: 2868560
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia.
Kolodgie FD; Dawson AK; Roden DM; Forman MB; Virmani R
Am Heart J; 1986 Dec; 112(6):1192-201. PubMed ID: 3788766
[TBL] [Abstract][Full Text] [Related]
3. The effect of perfluorochemical fluosol-DA (20%) on myocardial infarct healing in the rabbit.
Virmani R; Osmialowski AF; Kolodgie FD; Forman MB
Am J Cardiovasc Pathol; 1990; 3(1):69-80. PubMed ID: 2331363
[TBL] [Abstract][Full Text] [Related]
4. Beneficial long-term effect of intracoronary perfluorochemical on infarct size and ventricular function in a canine reperfusion model.
Forman MB; Puett DW; Wilson BH; Vaughn WK; Friesinger GC; Virmani R
J Am Coll Cardiol; 1987 May; 9(5):1082-90. PubMed ID: 3571747
[TBL] [Abstract][Full Text] [Related]
5. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB
Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
[TBL] [Abstract][Full Text] [Related]
6. Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocytes.
Kolodgie FD; Farb A; Carlson GC; Wilson PS; Virmani R
J Am Coll Cardiol; 1994 Oct; 24(4):1098-108. PubMed ID: 7930204
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion.
Forman MB; Pitarys CJ; Vildibill HD; Lambert TL; Ingram DA; Virmani R; Murray JJ
J Am Coll Cardiol; 1992 Jan; 19(1):205-16. PubMed ID: 1729335
[TBL] [Abstract][Full Text] [Related]
8. Effect of fluocarbon exchange transfusion on myocardial infarction size in dogs.
Nunn GR; Dance G; Peters J; Cohn LH
Am J Cardiol; 1983 Jul; 52(1):203-5. PubMed ID: 6858913
[TBL] [Abstract][Full Text] [Related]
9. Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion.
Forman MB; Bingham S; Kopelman HA; Wehr C; Sandler MP; Kolodgie F; Vaughn WK; Friesinger GC; Virmani R
Circulation; 1985 May; 71(5):1060-8. PubMed ID: 3986976
[TBL] [Abstract][Full Text] [Related]
10. Limitation of no reflow injury by blood-free reperfusion with oxygenated perfluorochemical (Fluosol-DA 20%).
Kolodgie FD; Virmani R; Farb A
J Am Coll Cardiol; 1991 Jul; 18(1):215-23. PubMed ID: 2050924
[TBL] [Abstract][Full Text] [Related]
11. Failure of fluosol DA to enhance the ultrasonic image of infarcted myocardium.
Vasey CG; Armstrong WF; West SR; Waller BF; Dillon JC; Feigenbaum H
J Clin Ultrasound; 1986 Oct; 14(8):613-8. PubMed ID: 3095392
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent reduction of myocardial infarct size with the perfluorochemical Fluosol-DA.
Rice HE; Virmani R; Hart CL; Kolodgie FD; Farb A
Am Heart J; 1990 Nov; 120(5):1039-46. PubMed ID: 2239656
[TBL] [Abstract][Full Text] [Related]
13. Effects of intracoronary infusion of arterial blood or Fluosol-DA 20% on regional myocardial metabolism and function during brief coronary artery occlusions.
Tokioka H; Miyazaki A; Fung P; Rajagopalan RE; Kar S; Meerbaum S; Corday E; Drury JK
Circulation; 1987 Feb; 75(2):473-81. PubMed ID: 2948736
[TBL] [Abstract][Full Text] [Related]
14. Cardioplegic protection with hypothermic K-Fluosol DA and K/Mg-Fluosol DA solutions.
Kyösola K; Harjula A; Mattila S; Aalto-Setälä K; Mattila I; Mattila P; Salmenperä M; Merikallio E
Scand J Thorac Cardiovasc Surg; 1985; 19(3):267-72. PubMed ID: 4081676
[TBL] [Abstract][Full Text] [Related]
15. Myocardial protection by perfluorochemical infusion during transient ischemia produced by balloon coronary occlusion.
Virmani R; Kolodgie FD; Osmialowski A; Zimmerman P; Mergner W; Forman MB
Am Heart J; 1988 Aug; 116(2 Pt 1):421-31. PubMed ID: 2969667
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of Fluosol-DA in acute cerebral ischemia.
Peerless SJ; Ishikawa R; Hunter IG; Peerless MJ
Stroke; 1981; 12(5):558-63. PubMed ID: 6795765
[TBL] [Abstract][Full Text] [Related]
17. Preservation of endothelial cell structure and function by intracoronary perfluorochemical in a canine preparation of reperfusion.
Forman MB; Puett DW; Bingham SE; Virmani R; Tantengco MV; Light RT; Bajaj A; Price R; Friesinger G
Circulation; 1987 Aug; 76(2):469-79. PubMed ID: 3608128
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effect of fluosol DA and dextran 40 on regional cerebral blood flow, infarction size, and mortality in cats with temporary occlusion of the middle cerebral artery.
Kolluri S; Heros RC; Hedley-Whyte ET; Vonsattel JP; Miller D; Zervas NT
Surg Neurol; 1986 Jul; 26(1):3-8. PubMed ID: 2424107
[TBL] [Abstract][Full Text] [Related]
19. Experimental studies on fluosol DA administration in acute pancreatitis.
Ohyanagi H; Ohashi O; Nakayama S; Yamamoto M; Okumura S; Saitoh Y
Biomater Artif Cells Artif Organs; 1988; 16(1-3):585-94. PubMed ID: 3179491
[TBL] [Abstract][Full Text] [Related]
20. Modification of cerebral ischemia with Fluosol.
Peerless SJ; Nakamura R; Rodriguez-Salazar A; Hunter IG
Stroke; 1985; 16(1):38-43. PubMed ID: 3966263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
